FARMINGDALE, N.Y., Feb. 4 /PRNewswire-FirstCall/ -- Misonix, Inc. , a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Hemax Medical, based in Hvidovre, Denmark, for the distribution of the BoneScalpel(TM) Ultrasonic Bone Cutter.
Hemax Medical is well known as an innovative market leader, having built a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis in neuro and spine surgery.
“Misonix welcomes Hemax Medical to our rapidly expanding sales and distribution organization in Europe. Hemax comes to us with an established reputation as a top tier distributor of advanced medical equipment in Scandinavia,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
CONTACT: Richard Zaremba, Misonix, Inc., +1-631-694-9555,
invest@misonix.com; Investor Relations: Kevin McGrath, Cameron Associates,
Inc., +1-212-245-4577, Kevin@cameronassoc.com
Web site: http://www.misonix.com/
